Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns (PHOENIX)
A Prospective, Multicenter, Randomized, Controlled Clinical Investigation Evaluating the Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft vs Standard of Care in the Treatment of Partial Thickness Thermal Burns
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Cellution Research
- Phone Number: 6035574660
- Email: clinical@cellutionbiologics.com
Study Contact Backup
- Name: Bryanna Finstein
- Phone Number: 6035574660
- Email: bryanna.f@cellutionbiologics.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age or older
- One or more thermal burns classified as either superficial partial thickness or deep partial thickness.
- Total Body Surface Area (TBSA) involvement between 5% and 15%.
- Total burn index wound area is greater than 25 cm 2 and less than 0.25 m 2 (2500 cm 2 )
- 1 If 2 or more burns are present, each must have an area greater than 15 cm 2
- The participant must be willing and able to participate in the informed consent process.
Exclusion Criteria:
- Full thickness burns.
- Burns present for >72 hours prior to study evaluation
- Burns requiring immediate autografting.
- Superficial burns (1 st -degree) or burns not meeting criteria to be included in TBSA calculations.
- Chemical or electrical burns.
- Burns secondary to blast injury.
- Burns causing vascular or respiratory compromise and burns requiring escharotomy
- Any severe systemic comorbidities which could impair healing (e.g. active sepsis or major organ failure).
- Known coagulopathy, platelet disorder, INR > 1.6, PTT > 38s, or platelets < 50,000 per mm 3
- Uncontrolled diabetes.
- Known life expectancy of < 6 months.
- Evidence of active infection in burn.
- Target area for treatment includes the head, neck, palms of hands, soles of the feet, or genitals.
- Viral infection which could impair healing or immune function (e.g. HIV, HBV, HCV)
- Participants of childbearing potential who are pregnant, considering becoming pregnant within the next 6 months, and/or are unwilling to utilize an appropriate form of contraception.
- Currently requiring dialysis or planning to start within 6 months.
- Medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments.
- Treated with hyperbaric oxygen therapy or a skin substitute within the 30 days prior to screening visit.
- Sensitivity to ofloxacin, vancomycin, or amphotericin antibiotics.
- Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 10 weeks, whichever occurs first.
|
Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound.
This is achieved through wound cleansing, debridement, offloading and moisture balance.
|
|
Experimental: AIC and Standard of Care
Participants with a thermal burn classified as either superficial partial thickness or deep partial thickness will receive treatment with an Amnion-Intermediate-Chorion (AIC) sheet product, a dehydrated multilayer human placental tissue derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 10 weeks, whichever occurs first.
|
Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound.
This is achieved through wound cleansing, debridement, offloading and moisture balance.
Dehydrated human placental multilayer allograft derived from donated human tissue.
AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Complete Epithelialization
Time Frame: 1-10 weeks
|
Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound.
This is achieved through wound cleansing, debridement, offloading and moisture balance.
|
1-10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Burn Area Change
Time Frame: 1-10 weeks
|
To evaluate the difference in percentage reduction in burn wound area at each follow-up visit in participants receiving dHAICM versus SOC alone.
|
1-10 weeks
|
|
Frequency of Full Epithelialization
Time Frame: 1-10 weeks
|
To compare the frequency of full epithelialization at 3 weeks in participants receiving dHAICM versus SOC alone.
|
1-10 weeks
|
|
Changes in Pain Scores Associated with Target Burns
Time Frame: 1-10 weeks
|
To determine the reduction in pain scores (VAS) for participants during dressing changes.
|
1-10 weeks
|
|
Changes in Scarring Quality of Target Burn
Time Frame: 1-10 weeks
|
To determine the difference in assessment of scarring quality using the Vancouver Scar Scale (VSS).
|
1-10 weeks
|
|
Incidents of Adverse Events
Time Frame: 1-10 weeks
|
To determine the difference in the frequency and nature of adverse events in participants receiving dHAICM versus SOC alone.
|
1-10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Director, Cellution Biologics
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CELLBIO-2026-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.